Global Adult Preventable Vaccines Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Adult Preventable Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Adult Preventable Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Adult Preventable Vaccines market include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Adult Preventable Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Adult Preventable Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Adult Preventable Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adult Preventable Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Adult Preventable Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Adult Preventable Vaccines sales, projected growth trends, production technology, application and end-user industry.

Adult Preventable Vaccines Segment by Company

Sanofi Pasteur
Johnson & Johnson (Janssen)
Pfizer Inc.
GlaxoSmithKline plc (GSK)
Sinovac Biotech
Sinopharm Group Co.,
Serum Institute of India Pvt.
Novavax, Inc.
Moderna, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Daiichi Sankyo Company
CSL Limited (Seqirus)
Bharat Biotech International
AstraZeneca plc

Adult Preventable Vaccines Segment by Type

Viral Vector Vaccines
Peptide Vaccines
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines

Adult Preventable Vaccines Segment by Application

Prevent Herpes Zoster
Prevent Pneumococcal Infection
Prevent Influenza
Prevent Human Papillomavirus (Hpv)
Prevent Hepatitis B
Other

Adult Preventable Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Adult Preventable Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Adult Preventable Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Adult Preventable Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Adult Preventable Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adult Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult Preventable Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adult Preventable Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adult Preventable Vaccines industry.
Chapter 3: Detailed analysis of Adult Preventable Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Adult Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Adult Preventable Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Adult Preventable Vaccines Sales Value (2020-2031)
1.2.2 Global Adult Preventable Vaccines Sales Volume (2020-2031)
1.2.3 Global Adult Preventable Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Adult Preventable Vaccines Market Dynamics
2.1 Adult Preventable Vaccines Industry Trends
2.2 Adult Preventable Vaccines Industry Drivers
2.3 Adult Preventable Vaccines Industry Opportunities and Challenges
2.4 Adult Preventable Vaccines Industry Restraints
3 Adult Preventable Vaccines Market by Company
3.1 Global Adult Preventable Vaccines Company Revenue Ranking in 2024
3.2 Global Adult Preventable Vaccines Revenue by Company (2020-2025)
3.3 Global Adult Preventable Vaccines Sales Volume by Company (2020-2025)
3.4 Global Adult Preventable Vaccines Average Price by Company (2020-2025)
3.5 Global Adult Preventable Vaccines Company Ranking (2023-2025)
3.6 Global Adult Preventable Vaccines Company Manufacturing Base and Headquarters
3.7 Global Adult Preventable Vaccines Company Product Type and Application
3.8 Global Adult Preventable Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Adult Preventable Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Adult Preventable Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Adult Preventable Vaccines Market by Type
4.1 Adult Preventable Vaccines Type Introduction
4.1.1 Viral Vector Vaccines
4.1.2 Peptide Vaccines
4.1.3 Inactivated Vaccines
4.1.4 Subunit Vaccines
4.1.5 Mrna Vaccines
4.2 Global Adult Preventable Vaccines Sales Volume by Type
4.2.1 Global Adult Preventable Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Adult Preventable Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global Adult Preventable Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global Adult Preventable Vaccines Sales Value by Type
4.3.1 Global Adult Preventable Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Adult Preventable Vaccines Sales Value by Type (2020-2031)
4.3.3 Global Adult Preventable Vaccines Sales Value Share by Type (2020-2031)
5 Adult Preventable Vaccines Market by Application
5.1 Adult Preventable Vaccines Application Introduction
5.1.1 Prevent Herpes Zoster
5.1.2 Prevent Pneumococcal Infection
5.1.3 Prevent Influenza
5.1.4 Prevent Human Papillomavirus (Hpv)
5.1.5 Prevent Hepatitis B
5.1.6 Other
5.2 Global Adult Preventable Vaccines Sales Volume by Application
5.2.1 Global Adult Preventable Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Adult Preventable Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global Adult Preventable Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global Adult Preventable Vaccines Sales Value by Application
5.3.1 Global Adult Preventable Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Adult Preventable Vaccines Sales Value by Application (2020-2031)
5.3.3 Global Adult Preventable Vaccines Sales Value Share by Application (2020-2031)
6 Adult Preventable Vaccines Regional Sales and Value Analysis
6.1 Global Adult Preventable Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Adult Preventable Vaccines Sales by Region (2020-2031)
6.2.1 Global Adult Preventable Vaccines Sales by Region: 2020-2025
6.2.2 Global Adult Preventable Vaccines Sales by Region (2026-2031)
6.3 Global Adult Preventable Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Adult Preventable Vaccines Sales Value by Region (2020-2031)
6.4.1 Global Adult Preventable Vaccines Sales Value by Region: 2020-2025
6.4.2 Global Adult Preventable Vaccines Sales Value by Region (2026-2031)
6.5 Global Adult Preventable Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Adult Preventable Vaccines Sales Value (2020-2031)
6.6.2 North America Adult Preventable Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Adult Preventable Vaccines Sales Value (2020-2031)
6.7.2 Europe Adult Preventable Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Adult Preventable Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific Adult Preventable Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Adult Preventable Vaccines Sales Value (2020-2031)
6.9.2 South America Adult Preventable Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Adult Preventable Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa Adult Preventable Vaccines Sales Value Share by Country, 2024 VS 2031
7 Adult Preventable Vaccines Country-level Sales and Value Analysis
7.1 Global Adult Preventable Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Adult Preventable Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Adult Preventable Vaccines Sales by Country (2020-2031)
7.3.1 Global Adult Preventable Vaccines Sales by Country (2020-2025)
7.3.2 Global Adult Preventable Vaccines Sales by Country (2026-2031)
7.4 Global Adult Preventable Vaccines Sales Value by Country (2020-2031)
7.4.1 Global Adult Preventable Vaccines Sales Value by Country (2020-2025)
7.4.2 Global Adult Preventable Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Adult Preventable Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Sanofi Pasteur
8.1.1 Sanofi Pasteur Comapny Information
8.1.2 Sanofi Pasteur Business Overview
8.1.3 Sanofi Pasteur Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 Sanofi Pasteur Adult Preventable Vaccines Product Portfolio
8.1.5 Sanofi Pasteur Recent Developments
8.2 Johnson & Johnson (Janssen)
8.2.1 Johnson & Johnson (Janssen) Comapny Information
8.2.2 Johnson & Johnson (Janssen) Business Overview
8.2.3 Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio
8.2.5 Johnson & Johnson (Janssen) Recent Developments
8.3 Pfizer Inc.
8.3.1 Pfizer Inc. Comapny Information
8.3.2 Pfizer Inc. Business Overview
8.3.3 Pfizer Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 Pfizer Inc. Adult Preventable Vaccines Product Portfolio
8.3.5 Pfizer Inc. Recent Developments
8.4 GlaxoSmithKline plc (GSK)
8.4.1 GlaxoSmithKline plc (GSK) Comapny Information
8.4.2 GlaxoSmithKline plc (GSK) Business Overview
8.4.3 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio
8.4.5 GlaxoSmithKline plc (GSK) Recent Developments
8.5 Sinovac Biotech
8.5.1 Sinovac Biotech Comapny Information
8.5.2 Sinovac Biotech Business Overview
8.5.3 Sinovac Biotech Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 Sinovac Biotech Adult Preventable Vaccines Product Portfolio
8.5.5 Sinovac Biotech Recent Developments
8.6 Sinopharm Group Co.,
8.6.1 Sinopharm Group Co., Comapny Information
8.6.2 Sinopharm Group Co., Business Overview
8.6.3 Sinopharm Group Co., Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio
8.6.5 Sinopharm Group Co., Recent Developments
8.7 Serum Institute of India Pvt.
8.7.1 Serum Institute of India Pvt. Comapny Information
8.7.2 Serum Institute of India Pvt. Business Overview
8.7.3 Serum Institute of India Pvt. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio
8.7.5 Serum Institute of India Pvt. Recent Developments
8.8 Novavax, Inc.
8.8.1 Novavax, Inc. Comapny Information
8.8.2 Novavax, Inc. Business Overview
8.8.3 Novavax, Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.8.4 Novavax, Inc. Adult Preventable Vaccines Product Portfolio
8.8.5 Novavax, Inc. Recent Developments
8.9 Moderna, Inc.
8.9.1 Moderna, Inc. Comapny Information
8.9.2 Moderna, Inc. Business Overview
8.9.3 Moderna, Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.9.4 Moderna, Inc. Adult Preventable Vaccines Product Portfolio
8.9.5 Moderna, Inc. Recent Developments
8.10 Merck & Co., Inc.
8.10.1 Merck & Co., Inc. Comapny Information
8.10.2 Merck & Co., Inc. Business Overview
8.10.3 Merck & Co., Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.10.4 Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio
8.10.5 Merck & Co., Inc. Recent Developments
8.11 Emergent BioSolutions Inc.
8.11.1 Emergent BioSolutions Inc. Comapny Information
8.11.2 Emergent BioSolutions Inc. Business Overview
8.11.3 Emergent BioSolutions Inc. Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.11.4 Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio
8.11.5 Emergent BioSolutions Inc. Recent Developments
8.12 Daiichi Sankyo Company
8.12.1 Daiichi Sankyo Company Comapny Information
8.12.2 Daiichi Sankyo Company Business Overview
8.12.3 Daiichi Sankyo Company Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.12.4 Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio
8.12.5 Daiichi Sankyo Company Recent Developments
8.13 CSL Limited (Seqirus)
8.13.1 CSL Limited (Seqirus) Comapny Information
8.13.2 CSL Limited (Seqirus) Business Overview
8.13.3 CSL Limited (Seqirus) Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.13.4 CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio
8.13.5 CSL Limited (Seqirus) Recent Developments
8.14 Bharat Biotech International
8.14.1 Bharat Biotech International Comapny Information
8.14.2 Bharat Biotech International Business Overview
8.14.3 Bharat Biotech International Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.14.4 Bharat Biotech International Adult Preventable Vaccines Product Portfolio
8.14.5 Bharat Biotech International Recent Developments
8.15 AstraZeneca plc
8.15.1 AstraZeneca plc Comapny Information
8.15.2 AstraZeneca plc Business Overview
8.15.3 AstraZeneca plc Adult Preventable Vaccines Sales, Value and Gross Margin (2020-2025)
8.15.4 AstraZeneca plc Adult Preventable Vaccines Product Portfolio
8.15.5 AstraZeneca plc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Adult Preventable Vaccines Value Chain Analysis
9.1.1 Adult Preventable Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Adult Preventable Vaccines Sales Mode & Process
9.2 Adult Preventable Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Adult Preventable Vaccines Distributors
9.2.3 Adult Preventable Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings